Brokers Set Expectations for Audentes Therapeutics Inc’s FY2020 Earnings (BOLD)
Audentes Therapeutics Inc (NASDAQ:BOLD) – Equities researchers at Wedbush boosted their FY2020 earnings estimates for shares of Audentes Therapeutics in a note issued to investors on Tuesday, April 9th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($4.13) for the year, up from their previous forecast of ($4.24). Wedbush has a “Outperform” rating and a $57.00 price target on the stock. Wedbush also issued estimates for Audentes Therapeutics’ FY2021 earnings at ($3.10) EPS and FY2022 earnings at ($0.21) EPS.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.08. During the same period last year, the company earned ($0.82) earnings per share.
Shares of BOLD opened at $41.00 on Thursday. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -12.06 and a beta of 1.96. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $46.18.
A number of large investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC boosted its position in Audentes Therapeutics by 8.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 13,184 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 1,053 shares during the last quarter. NumerixS Investment Technologies Inc lifted its position in shares of Audentes Therapeutics by 1,200.0% during the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,200 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Audentes Therapeutics by 2.3% during the third quarter. Teachers Advisors LLC now owns 65,670 shares of the biotechnology company’s stock worth $2,600,000 after purchasing an additional 1,470 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Audentes Therapeutics by 46.1% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 1,983 shares during the last quarter.
In related news, Director Louis G. Lange sold 20,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the sale, the director now directly owns 306,099 shares in the company, valued at approximately $11,019,564. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 21,000 shares of the stock in a transaction on Monday, February 25th. The shares were sold at an average price of $30.00, for a total value of $630,000.00. Following the completion of the sale, the chief executive officer now owns 135,700 shares of the company’s stock, valued at $4,071,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,000 shares of company stock valued at $1,650,600. 6.60% of the stock is owned by insiders.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: Call Option Volume
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.